By Gilang Cahya 
A groundbreaking study has mapped the intricate genetic landscape of Wilms tumour, a common childhood kidney cancer, offering a new paradigm for personalised treatment strategies. Researchers from the Wellcome Sanger Institute, Cambridge University Hospitals NHS Foundation Trust, Great Ormond Street Hospital, and the University of Würzburg, alongside their international collaborators, have identified how inherited genetic variations influence the development of this disease. This discovery holds the potential to refine treatment plans, ensuring greater efficacy while significantly minimising the harsh side effects often associated with paediatric cancer therapies.
Unraveling the Genetic Blueprint of Wilms Tumour
Wilms tumour, primarily affecting children under the age of five, impacts approximately 85 children annually in the United Kingdom. While the cancer can arise from spontaneous genetic mutations during foetal development, a significant portion, around 30 percent, is linked to an inherited genetic predisposition that elevates the risk of developing the disease. This new research, published in the prestigious journal Cancer Discovery, provides compelling evidence that these inherited genetic changes not only predispose individuals to Wilms tumour but also predetermine the tumour’s developmental trajectory, its responsiveness to specific treatments, and the individual’s likelihood of developing secondary cancers later in life.
The study meticulously analysed the genetic differences across a cohort of children diagnosed with Wilms tumour. By genetically mapping several hundred tissue samples from 137 children, including 71 with a known genetic predisposition, the research team was able to discern distinct patterns of tumour development. They observed that inherited genetic predispositions lead to different tumour development pathways and variations in kidney structures. Crucially, they identified specific genetic predispositions that appear to restrict tumour growth, while also highlighting how Wilms tumours develop differently in children without these inherited genetic factors.
The Impact of Inherited Predispositions on Tumour Development
A key finding of the study is that the manner in which Wilms tumours develop is intricately linked to the specific inherited genetic change and, critically, the timing of its activation during foetal development. Different genetic predispositions were shown to result in distinct DNA changes, known as driver mutations, that initiate tumour formation. Some of these driver mutations were found to increase the risk of both Wilms tumour and secondary cancers.
Specifically, the researchers pinpointed genetic alterations in the WT1 and TRIM28 genes. Mutations in these genes were associated with the accumulation of additional driver mutations within specific cellular pathways. This discovery is particularly significant as it suggests these pathways could become prime targets for future therapeutic interventions. By understanding these precise genetic sequences that drive tumour progression, scientists may be able to develop novel therapies that directly interfere with or halt cancer formation at its earliest stages.
Furthermore, the study revealed that genetic predisposition also influences the architectural development of kidney tissue. This could offer an explanation for why some children develop benign kidney growths preceding the onset of cancerous tumours. This detailed understanding of the genetic underpinnings allows for a more nuanced view of Wilms tumour, moving beyond a singular diagnosis to a spectrum of genetically driven diseases.
Towards Personalised Treatment and Screening Strategies
The implications of this research for clinical practice are profound. Currently, the treatment of Wilms tumour in predisposed children involves a delicate balancing act: ensuring sufficient tumour removal to mitigate the risk of secondary cancers while preserving as much kidney function as possible. This often entails a combination of chemotherapy, specific surgical techniques, extended post-operative chemotherapy, and rigorous surveillance for recurrence.
However, the current clinical management of children with a known genetic predisposition differs from those with spontaneous mutations due to the heightened risk of secondary cancers. The findings from this study suggest that this one-size-fits-all approach for predisposed children may not be optimal. By understanding a child’s specific genetic makeup, clinicians could potentially tailor treatment and screening programmes to their individual risk profile.
Professor Sam Behjati, co-senior author from the Wellcome Sanger Institute and Cambridge University Hospitals NHS Foundation Trust, elaborated on this point: "At the moment, we treat all children with a predisposition the same, meaning that some children get too much and others too little treatment. Our findings indicate that we may be able to personalise treatment on the basis of genetic information." This could lead to less aggressive treatment for children with a lower risk of secondary cancers, thereby reducing the long-term physical and psychological burden of treatment, and conversely, more intensive management for those with a higher genetic risk.
The Role of Early Detection and Prevention
Beyond refining existing treatments, this research opens avenues for improved screening and even potential prevention strategies. The identification of specific genetic changes that drive tumour development could enable more accurate and targeted screening programmes. This may allow for earlier detection of tumours, potentially leading to less invasive surgical interventions.
"Moreover, since we now know the precise sequence of genetic changes that lead from predisposition to cancer, we may be able to screen for tumours more effectively and even begin to entertain the possibility of prevention," Professor Behjati added. This forward-looking perspective highlights the transformative potential of genomic research in paediatric oncology.
A Collaborative Effort for Better Patient Outcomes
The success of this comprehensive study is a testament to the power of international collaboration and multidisciplinary research. The involvement of leading institutions like the Wellcome Sanger Institute, Cambridge University Hospitals, and Great Ormond Street Hospital underscores a collective commitment to advancing paediatric cancer care.
Dr. Taryn Treger, co-first author from the Wellcome Sanger Institute, emphasised the significance of understanding the different ways cancers develop based on underlying genetic changes. "This means that in some predispositions we can exactly predict what additional genetic changes lead to cancer development, paving the path to identify treatments that interfere with cancer formation in the first place," she stated. This predictive power is crucial for developing proactive therapeutic strategies.
The research has also garnered support from organisations dedicated to improving the lives of children affected by cancer. Phil Brace, Chief Executive of The Little Princess Trust, a charity that supported this research, highlighted the crucial need to fund studies that not only aim to improve survival rates but also mitigate treatment side effects. "Childhood cancer treatment can have substantial adverse effects that impact the child living with the condition, and those around them," Brace commented. "We are hopeful that this research may help tailor treatments in the future."
Looking Ahead: The Future of Wilms Tumour Management
The implications of this research extend beyond the immediate management of Wilms tumour. It provides a robust framework for understanding how inherited genetic variations contribute to cancer development in children. This knowledge can inform future research into other paediatric cancers with genetic predispositions, potentially leading to similar breakthroughs in personalised medicine.
The ability to tailor treatment based on an individual’s genetic profile represents a significant shift in oncology. For children and their families, this means a future where cancer treatment is not only more effective in eradicating the disease but also gentler, preserving vital organ function and reducing the long-term health consequences of aggressive therapies. The research signifies a crucial step towards a future where paediatric cancer care is truly personalised, optimising outcomes and enhancing the quality of life for young patients. This collaborative effort exemplifies the immense potential of genomic research to translate complex scientific discoveries into tangible benefits for those who need it most.
